Short answer
Liquidia Corp (LQDA) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement). Continued YUTREPIA marketing, but PH-ILD indication and promotion permanently removed, narrowing the product’s addressable market.
Liquidia Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Continued YUTREPIA marketing, but PH-ILD indication and promotion permanently removed, narrowing the product’s addressable market
- $320.4M total UTC payments, including $175.0M within 30 business days and $145.4M in installments by January 31 and April 30, 2027
- Additional settlement obligations: $21.75M to Sandoz, $19.05M to Henderson and $19.45M to PBM, totaling $380.65M
- Litigation dismissals and releases conditional on payments and FDA approval removing PH-ILD from YUTREPIA labeling
- HCR consent increased minimum cash covenant from $15.0M to $45.0M, intensifying liquidity requirements
Item 1.02 · Termination of a Material Definitive Agreement
- Three legacy agreements terminate only after settlement payments are made, creating execution risk before Liquidia gains full contractual release
- Promotion Agreement ends for RareGen Litigation proceeds after the Sandoz payment, preserving certain third-quarter 2026 payment obligations
- Henderson’s $10.0 million litigation financing terminates upon full repayment, eliminating its liens and priority rights over litigation proceeds
- PBM’s litigation-control and indemnification rights terminate upon payment, potentially restoring Liquidia PAH’s economic exposure to RareGen Litigation
- Settlement payments restructure claims on litigation proceeds, materially affecting Liquidia’s potential recovery and remaining obligations
Item 7.01 · Regulation FD Disclosure
- Cash and equivalents of $396.1 million as of September 30, 2026, supporting near-term operations and development funding
- Settlement-related payments, Sandoz agreements and Treprostinil Injection rights transfer could materially alter cash flows
- PH-ILD label removal and promotion cessation risk to YUTREPIA revenue, while PAH availability continues
- Pipeline focus remains L606 and YUTREPIA opportunities in SSc-RP, PH-COPD and other indications
- Preliminary unaudited September 30, 2026 financial information remains subject to accounting adjustments and review
Item 8.01 · Other Events
- Liquidia settled all ongoing litigation with UTC, eliminating a major legal overhang
- Concurrent Sandoz, Henderson and PBM agreements address antitrust and breach-of-contract claims tied to RareGen Litigation
- Settlement structure links multiple agreements, potentially affecting Liquidia’s commercial and litigation obligations
- Exhibit 99.1 contains the substantive settlement terms and investor-relevant details
Item EX-99.1 · Exhibit EX-99.1
- Global settlement ends all six lawsuits with United Therapeutics, removing litigation overhang and securing uninterrupted PAH commercialization
- $380.7M net payments across 2026 and 2027, including $175M within 30 business days and $145.4M in two installments
- PH-ILD indication removed from YUTREPIA labeling after Liquidia accepted the ’327 patent ruling and waived appeal
- Q3’26 preliminary YUTREPIA sales reached $222.7M, supporting $396.1M cash and equivalents at September 30, 2026
- Treprostinil Injection promotional agreement terminated, ending Liquidia’s commercial support for that product
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Liquidia Corp 8-K filings
Get the next LQDA 8-K as it lands
Follow LQDA for push alerts, or ask the research agent what this filing means.